Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-18
Publisher
Informa UK Limited
Online
2021-09-13
DOI
10.1080/14737140.2021.1979396
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
- (2021) Daniel A Zlotoff et al. Journal for ImmunoTherapy of Cancer
- Cancer Therapeutics–related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation
- (2021) Shira Peleg Hasson et al. JOURNAL OF IMMUNOTHERAPY
- Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis
- (2021) Paaladinesh Thavendiranathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
- (2021) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- (2021) Julie R Brahmer et al. Journal for ImmunoTherapy of Cancer
- Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
- (2020) Lili Zhang et al. EUROPEAN HEART JOURNAL
- Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis
- (2020) Magid Awadalla et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis
- (2020) Shira Peleg Hasson et al. Clinical Research in Cardiology
- Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
- (2020) Thorsten Oliver Goetze et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.
- (2020) Melissa Lynne Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
- (2020) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity
- (2020) Arjun Khunger et al. Current Oncology Reports
- Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque
- (2020) Zsofia D. Drobni et al. CIRCULATION
- NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
- (2020) Vincenzo Quagliariello et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Colchicine in Patients with Chronic Coronary Disease
- (2020) Stefan M. Nidorf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
- (2020) Vincenzo Quagliariello et al. Journal of Personalized Medicine
- Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors
- (2020) Harish Seethapathy et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention
- (2020) Spencer C Wei et al. Cancer Discovery
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis
- (2019) Mehmet Altan et al. Journal of Thoracic Oncology
- LATE GADOLINIUM ENHANCEMENT IN PATIENTS WITH MYOCARDITIS FROM IMMUNE CHECKPOINT INHIBITORS
- (2019) Lili Zhang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Immune checkpoint blockade for organ transplant patients with advanced cancer
- (2019) Pauline De Bruyn et al. CURRENT OPINION IN ONCOLOGY
- T cell checkpoint regulators in the heart
- (2019) Nir Grabie et al. CARDIOVASCULAR RESEARCH
- Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors
- (2019) Nicolas Palaskas et al. AMERICAN JOURNAL OF CARDIOLOGY
- Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
- (2019) changhua ji et al. CLINICAL CANCER RESEARCH
- Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab
- (2019) V. Quagliariello et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
- (2019) Suheil Albert Atallah-Yunes et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Myocarditis in the Setting of Cancer Therapeutics
- (2019) Marc P. Bonaca et al. CIRCULATION
- Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
- (2019) Joe-Elie Salem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis
- (2019) Yoshito Zamami et al. JAMA Oncology
- Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
- (2019) Jair Bar et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
- (2019) Jean-Claude Tardif et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors
- (2019) Hajir Ibraheim et al. RHEUMATOLOGY
- Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
- (2019) Yu-Wen Zhou et al. Frontiers in Pharmacology
- Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab
- (2018) Shogo Yamaguchi et al. CANADIAN JOURNAL OF CARDIOLOGY
- Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area
- (2018) Hassan Mir et al. CANADIAN JOURNAL OF CARDIOLOGY
- Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
- (2018) Charlotte Schwab et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis
- (2018) Tom T.P. Seijkens et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor‐Associated Myocarditis
- (2018) Sarju Ganatra et al. ONCOLOGIST
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2018) Stephane Ederhy et al. JACC-Cardiovascular Imaging
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
- (2018) Ouidad Zehou et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Immune Checkpoint Inhibitor–Associated Myositis
- (2018) Céline Anquetil et al. CIRCULATION
- Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer
- (2018) Herbert H. Loong et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Immune checkpoint inhibitors and cardiovascular toxicity
- (2018) Alexander R Lyon et al. LANCET ONCOLOGY
- Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
- (2018) Mehdi Touat et al. NEUROLOGY
- Hepatotoxicity and Recurrent NSTEMI While on Pembrolizumab for Metastatic Giant Cell Bone Tumor
- (2018) Jennifer M. Kwan et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
- (2018) Alvaro Moreira et al. EUROPEAN JOURNAL OF CANCER
- What did we learn from CTLA-4 insufficiency on the human immune system?
- (2018) Noriko Mitsuiki et al. IMMUNOLOGICAL REVIEWS
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling
- (2017) Po-Lin Lin et al. EUROPEAN JOURNAL OF CANCER
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Smoldering myocarditis following immune checkpoint blockade
- (2017) Timothy G. Norwood et al. Journal for ImmunoTherapy of Cancer
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy
- (2016) Robert D. Anderson et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects
- (2016) Bodo Grimbacher et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
- (2016) Marije Baas et al. eLife
- Myocarditis with very high troponins: risk stratification by cardiac magnetic resonance
- (2016) Rajesh Janardhanan Journal of Thoracic Disease
- Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
- (2016) Lucie Heinzerling et al. Journal for ImmunoTherapy of Cancer
- Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
- (2016) Viktor H. Koelzer et al. Journal for ImmunoTherapy of Cancer
- Regulatory T-cells in autoimmune diseases: Challenges, controversies and—yet—unanswered questions
- (2015) Charlotte R. Grant et al. AUTOIMMUNITY REVIEWS
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology
- (2015) Alexander R. Lyon et al. EUROPEAN JOURNAL OF HEART FAILURE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
- (2015) Benjamin P Geisler et al. Journal for ImmunoTherapy of Cancer
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice
- (2014) J. A. Lucas et al. JOURNAL OF IMMUNOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
- (2014) Desirée Schubert et al. NATURE MEDICINE
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
- (2013) Elena Gianchecchi et al. AUTOIMMUNITY REVIEWS
- Autoimmunity in viral myocarditis
- (2013) Jay Reddy et al. CURRENT OPINION IN RHEUMATOLOGY
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
- (2013) A. L. P. Caforio et al. EUROPEAN HEART JOURNAL
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
- (2013) Philip S. Hall et al. JACC-Heart Failure
- Update on Myocarditis
- (2012) Ingrid Kindermann et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myocardial Infarction Triggers Chronic Cardiac Autoimmunity in Type 1 Diabetes
- (2012) R. V. S. R. K. Gottumukkala et al. Science Translational Medicine
- Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
- (2011) De-xiu Bu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion
- (2011) Kimberly A. Hofmeyer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
- (2011) Taku Okazaki et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
- (2011) O. S. Qureshi et al. SCIENCE
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
- (2010) C. Ralph et al. CLINICAL CANCER RESEARCH
- PD-1 deficiency results in the development of fatal myocarditis in MRL mice
- (2010) Jian Wang et al. INTERNATIONAL IMMUNOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitogen-Activated Protein Kinase Signaling in the Heart: Angels Versus Demons in a Heart-Breaking Tale
- (2010) Beth A. Rose et al. PHYSIOLOGICAL REVIEWS
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis
- (2008) Jun Lee et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search